Floatz logo

Toripalimab

Surufatinib

Sun Yat-sen Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Surufatinib cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 2CCC
Surufatinib
Sun Yat-sen University
Phase 2CCC
Tislelizumab
Sun Yat-sen University
Phase 2CCC
Docetaxel
Sun Yat-sen University
Phase 2CCC
Pyrotinib
Sun Yat-sen University
Phase 2CCC
rc48-adc
Sun Yat-sen University
Phase 2CCC

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →